Company: SXTPW
Filing Date: 2025-08-15
Form Type: PRE 14A
Source: 0001213900-25-077435
Chunk: 35

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-08-15
Form: PRE 14A
Chunk 35
---
 employment for any reason other than Cause or
Disability, as defined in the Dow Employment Agreement, or (ii) Dr. Dow terminates his employment for Good Reason, Dr. Dow will be entitled
to Change in Control severance.

Dr. Dow is subject to
non-competition and non-solicitation during the term of his employment and for a period of 24 months after termination of his employment.

Miller Employment Agreement. We entered into an Employment Agreement dated as of January 12, 2023 with Tyrone Miller (the “Miller Employment
Agreement”), our Chief Financial Officer. The term of the Miller Employment Agreement began on January 12, 2023 and will continue
for a period of two years, with subsequent automatic renewals unless either party thereto provides notice to terminate at least 90 days
prior to the applicable renewal date. The Miller Employment Agreement provides Mr. Miller an annual base salary of $204,000, bonuses to
the extent certain events occur or if applicable performance goals are met and employee benefits that are generally given to our senior
executives. In December 2024, the Board approved an increase to Mr. Miller’s base salary to $215,000 for fiscal year 2025. Contingent
on the receipt of shareholder approval to increase the number of shares available under the 2022 Plan, Mr. Miller was granted a five-year
option to purchase a total of 200 shares of our common stock that vest on the last day of each quarter in each calendar year (for a cumulative
total or no more than 4,000 shares over five years). The per share exercise price of the option was initially equal to the per share closing
price of our common stock on the date of the initial public offering and shall have a cashless exercise provision. In November 2023, the
Board reset the exercise price of the option to be equal to $60.00 and modified the vesting provisions of the option to vest annually
over five years, rather than quarterly, with the first vesting date being December 31, 2024. The initial grant and subsequent amendment
of Mr. Miller’s options was contingent upon the stockholders of the Company approving the amendment to the exercise price of the
options and approving the amendment to the 2022 Plan to increase the number of shares available under the 2022 Plan in order to comply
with Listing Rule 5635(c) of The Nasdaq Stock Market LLC. On July 16,